Fallopian tube as main source for ovarian and pelvic (nonendometrial) serous carcinomas

International Journal of Clinical and Experimental Pathology

Volumn 5, Issue 3, 2012, Pages 182-186

  Zheng, Wenxin ^a,b   Fadare, Oluwole ^c  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ANIMAL; CANCER GRADING; CARCINOMA; CHEMISTRY; EDITORIAL; EPITHELIUM CELL; FEMALE; NEOPLASM; OVARY TUMOR; PATHOLOGY; PELVIS TUMOR; PHENOTYPE; PROGNOSIS; UTERINE TUBE TUMOR;

ANIMALS; CARCINOMA; EPITHELIAL CELLS; FALLOPIAN TUBE NEOPLASMS; FEMALE; NEOPLASM GRADING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PELVIC NEOPLASMS; PHENOTYPE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861216477     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Editorial

References (45)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Krigman H, Bentley R, Robboy SJ. Pathology of epithelial ovarian tumors. Clin Obstet Gynecol 1994; 37: 475-491.
3. Fields MM, Chevlen E. Ovarian cancer screening: a look at the evidence. Clin J Oncol Nurs 2006; 10: 77-81.
4. Hensley ML, Castiel M, Robson ME. Screening for ovarian cancer: what we know, what we need to know. Oncology (Williston Park) 2000; 14: 1601-1607; discussion 1608, 1613-1606.
5. Bast RC Jr. Status of tumor markers in ovarian cancer screening. J Clin Oncol 2003; 21: 200s-205s.
6. Piver MS. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Oncologist 1996; 1: 326-330.
7. Brand AH. The RANZCOG College Statement on prophylactic oophorectomy in older women undergoing hysterectomy for benign disease: is the evidence sufficient to change practice? Aust N Z J Obstet Gynaecol 2011; 51: 296-300.
8. Jacobs I, Oram D. Prevention of ovarian cancer: a survey of the practice of prophylactic oophorectomy by fellows and members of the Royal College of Obstetricians and Gynaecologists. Br J Obstet Gynaecol 1989; 96: 510-515.
9. Schwartz PE. The role of prophylactic oophorectomy in the avoidance of ovarian cancer. Int J Gynaecol Obstet 1992; 39: 175-184.
10. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, Friedman C, Harlan L, Warren J, Anderson RN, Pickle LW. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005; 97: 1407-1427.
11. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007; 19: 3-9.
12. Fathalla MF. Incessant ovulation-a factor in ovarian neoplasia? Lancet 1971; 2: 163.
13. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983; 71: 717-721.
14. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001; 22: 255-288.
15. Resta L, Russo S, Colucci GA, Prat J. Morphologic precursors of ovarian epithelial tumors. Obstet Gynecol 1993; 82: 181-186.
16. Hutson R, Ramsdale J, Wells M. p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology 1995; 27: 367-371.
17. Mittal KR, Zeleniuch-Jacquotte A, Cooper JL, Demopoulos RI. Contralateral ovary in unilateral ovarian carcinoma: a search for preneoplastic lesions. Int J Gynecol Pathol 1993; 12: 59-63.
18. Tresserra F, Grases PJ, Labastida R, Ubeda A. Histological features of the contralateral ovary in patients with unilateral ovarian cancer: a case control study. Gynecol Oncol 1998; 71: 437-441.
19. Aoki Y, Kawada N, Tanaka K. Early form of ovarian cancer originating in inclusion cysts. A case report. J Reprod Med 2000; 45: 159-161.
20. Scully RE. Pathology of ovarian cancer precursors. J Cell Biochem Suppl 1995; 23: 208-218.
21. Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001; 38: 87-95.
22. Doran A. An unreported case of primary cancer of the fallopian tubes in 1847, with notes on primary tubal cancer. Trans Obstet Soc Lond 1896; 38: 322-326.
23. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee onGynecologic Oncology. Int J Gynaecol Obstet 2000; 70: 209-262.
24. Woolas R, Jacobs I, Davies AP, Leake J, Brown C, Grudzinskas JG, Oram D. What is the true incidence of primary fallopian tube carcinoma? Int J Gynecol Cancer 1994; 4: 384-388.
25. Hu CY, Taymor ML, Hertig AT. Primary carcinoma of the fallopian tube. Am J Obstet Gynecol 1950; 59: 58-67, illust.
26. Powell CB, Chen LM, McLennan J, Crawford B, Zaloudek C, Rabban JT, Moore DH, Ziegler J. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer 2011; 21: 846-851.
27. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30: 230-236.
28. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001; 195: 451-456.
29. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006; 296: 185-192.
30. Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 2002; 87: 52-56.
31. Carcangiu ML, Radice P, Manoukian S, Spatti G, Gobbo M, Pensotti V, Crucianelli R, Pasini B. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol 2004; 23: 35-40.
32. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, Berkowitz RS, Muto MG, Crum CP. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007; 31: 161-169.
33. Salvador S, Rempel A, Soslow RA, Gilks B, Huntsman D, Miller D. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol 2008; 110: 408-417.
34. Przybycin CG, Kurman RJ, Ronnett BM, Shih Ie M, Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 2010; 34: 1407-1416.
35. Mehrad M, Ning G, Chen EY, Mehra KK, Crum CP. A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube. Adv Anat Pathol 2010; 17: 293-302.
36. Singer G, Kurman RJ, Chang HW, Cho SK, Shih Ie M. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002; 160: 1223-1228.
37. Ho CL, Kurman RJ, Dehari R, Wang TL, Shih Ie M. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004; 64: 6915-6918.
38. Korner M, Burckhardt E, Mazzucchelli L. Different proportions of aneusomic cells in ovarian inclusion cysts associated with serous borderline tumours and serous high-grade carcinomas support different pathogenetic pathways. J Pathol 2005; 207: 20-26.
39. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004; 28: 496-504.
40. Li J, Abushahin N, Pang S, Xiang L, Chambers SK, Fadare O, Kong B, Zheng W. Tubal origin of 'ovarian' low-grade serous carcinoma. Mod Pathol 2011; 24: 1488-1499.
41. Boyd C, McCluggage WG. Low-Grade Ovarian Serous Neoplasms (Low-Grade Serous Carcinoma and Serous Borderline Tumor) Associated With High-Grade Serous Carcinoma or Undifferentiated Carcinoma: Report of a Series of Cases of an Unusual Phenomenon. Am J Surg Pathol 2012.
42. Dehari R, Kurman RJ, Logani S, Shih Ie M. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol 2007; 31: 1007-1012.
43. Cibula D, Widschwendter M, Majek O, Dusek L. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update 2011; 17: 55-67.
44. Hankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer MJ, Rosner B, Hennekens CH, Speizer PE. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 1993; 270: 2813-2818.
45. Kjaer SK, Mellemkjaer L, Brinton LA, Johansen C, Gridley G, Olsen JH. Tubal sterilization and risk of ovarian, endometrial and cervical cancer. A Danish population-based follow-up study of more than 65 000 sterilized women. Int J Epidemiol 2004; 33: 596-602.